

Frunevetmab Biosimilar - Research Grade

Product Code: ICH5559-10mg

More Information

Species Reactivity: Feline

Target: Felcat NGF

Concentration: >1mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Frunevetmab Biosimilar - Research Grade

Antibodies against the same target: [Relfovetmab Biosimilar - Research Grade \(ICH5814\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

Shipping Conditions: Blue ice

background: This is an unconjugated, non-therapeutic recombinant analog of frunevetmab (the originator behind Solensia), a felinized anti-nerve growth factor (NGF) monoclonal antibody. Supplied as a feline IgG1-kappa antibody built around the NGF target, it is intended strictly for research use only (RUO) and is not the clinical veterinary product; it is not for feline, other animal, or human use. The molecule binds and sequesters NGF, blocking NGF engagement of its receptors, making it a useful tool for studying neurotrophin biology, NGF-driven nociceptor sensitization, and pain-pathway pharmacology in in-vitro assays and preclinical models. Typical research applications include positive/reference controls in NGF neutralization and ligand-binding assays, benchmarking of anti-NGF biologics, ADCC/effector-function characterization, and antibody-engineering or assay-

development work. It is offered at research grade with low endotoxin (1 EU/mg; ultra-low 0.5 EU/mg options), in bulk milligram-to-gram quantities suitable for in-vivo standards and scaled experimentation. No clone identity is implied; the reagent is defined by its target specificity and IgG1-kappa framework. Nerve growth factor (NGF) is the prototypical neurotrophin, a secreted growth factor essential for the development, survival, and maintenance of sympathetic and sensory neurons. Mature NGF signals through two receptors: the high-affinity receptor tyrosine kinase TrkA (NTRK1), which drives neurotrophic and pro-nociceptive signaling, and the lower-affinity p75 neurotrophin receptor (p75NTR/NGFR), a TNF-receptor superfamily member that modulates survival and apoptotic signaling and can bind proNGF preferentially. In adult tissues, NGF is released by inflammatory and injured cells and is a key mediator of peripheral nociceptor sensitization, contributing to hyperalgesia and allodynia in inflammatory and osteoarthritic pain. Feline NGF is the species ortholog relevant to this reagent; the mature protein is highly conserved across mammals, so sequestering NGF prevents TrkA/p75NTR engagement and downstream pain signaling. NGF is therefore a central node in neurotrophin biology and analgesic drug discovery.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 3-4 weeks